DADarrell R. Abernethy

Darrell R. Abernethy

*This is an algorithmically generated author record based on publicly available information.

Darrell R. Abernethy has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of Wavelet and Fast Fourier Transforms in Pharmacodynamics

    by Donald E. Mager, Darrell R. Abernethy

    Progress has been made in the development and application of mechanism-based pharmacodynamic models for describing the drug-specific and physiological factors influencing the time course of responses to the diverse actions of drugs. However, the biological variability in biosignals and the complexity of pharmacological systems often complicate or preclude the direct application of traditional structural and nonstructural models. Mathematical transforms may be used to provide measures of drug effects, identify structural and temporal patterns, and visualize multidimensional data from analyses of biomedical signals and images. Fast Fourier transform (FFT) and wavelet analyses are two methodologies that have proven to be useful in this context. FFT converts a signal from the time domain to the frequency domain, whereas wavelet transforms colocalize in both domains and may be utilized effectively for nonstationary signals. Nonstationary drug effects are common but have not been well analyzed and characterized by other methods. In this review, we discuss specific applications of these transforms in pharmacodynamics and their potential role in ascertaining the dynamics of spatiotemporal properties of complex pharmacological systems.


  • Top Cited Papers
    Open Access

    A Drug Burden Index to Define the Functional Burden of Medications in Older People

    by Sarah N. Hilmer, Donald E. Mager, Eleanor M. Simonsick, Ying Cao, Shari M. Ling, B. Gwen Windham, Tamara B. Harris, Joseph T. Hanlon, Susan M. Rubin, Ronald I. Shorr, et al.

    Older people carry both a high burden of illness for which medications are indicated and an incompletely understood increased risk of adverse drug reactions.1-3 Evidence to guide prescribing is limited by the exclusion of older adults with multiple medical conditions from participation in controlled clinical trials. Determination of potentially inappropriate medication use in older people is guided predominantly by expert consensus statements such as the updated Beers criteria.4 Use of medications described as inappropriate by the Beers criteria has been associated with adverse health outcomes in nursing home residents5 and with poorer self-perceived health6 but not with decline in self-reported function.7 Development of an evidence-based approach to guide appropriate medication use, linking clinically relevant data such as functional measures to medication exposure, would be consistent with current practices in clinical decision making.8


  • Enantioselective separation and online affinity chromatographic characterization of R,R‐ and S,S‐fenoterol

    by Farideh Beigi, Carlo Bertucci, Weizhong Zhu, Khalid Chakir, Irving W. Wainer, Rui‐Ping Xiao, Darrell R. Abernethy

    Background: rac‐Fenoterol is a β2‐adrenoceptor agonist (β2‐AR) used in the treatment of asthma. It has two chiral centers and is marketed as a racemic mixture of R,R′‐ and S,S′‐fenoterol (R‐F and S‐F). Here we report the separation of the R‐F and S‐F enantiomers and the evaluation of their binding to and activation of the β2‐AR. Methods: R‐F and S‐F were separated from the enantiomeric mixture by chiral chromatography and absolute configuration determined by circular dichroism. β2‐AR binding was evaluated using frontal affinity chromatography with a stationary phase containing immobilized membranes from HEK‐293 cells that express human β2‐AR and standard membrane binding studies using the same membranes. The effect of R‐F and S‐F on cardiomyocyte contractility was also investigated using freshly isolated adult rat cardiomyocytes. Results: Chiral chromatography of rac‐fenoterol yielded separated peaks with an enantioselectivity factor of 1.21. The less retained peak was assigned the absolute configuration of S‐F and the more retained peak R‐F. Frontal chromatography using membrane‐bound β2‐AR as the stationary phase and rac‐3H‐fenoterol as a marker ligand showed that addition of increasing concentrations of R‐F to the mobile phase produced concentration‐dependent decreases in rac‐3H‐fenoterol retention, while similar addition of S‐F produced no change in rac‐3H‐fenoterol retention. The calculated dissociation constant of R‐F was 472 nM and the number of available binding sites 176 pmol/column, which was consistent with the results from the membrane binding study 460 ± 55 nM (R‐F) and 109,000 ± 10,400 nM (S‐F). In the cardiomyocytes, R‐F increased maximum contractile response from (265 ± 11.6)% to (306 ± 11.8)% of resting cell length (P < 0.05) and reduced EC50 from −7.0 ± 0.270 to −7.1 ± 0.2 log[M] (P < 0.05), while S‐F had no significant effect. Discussion: Previous studies have shown that rac‐fenoterol acts as an apparent β2‐AR/Gs selective agonist and fully restores diminished β2‐AR contractile response in cardiomyocytes from failing hearts of spontaneously hypertensive rats (SHR). Here we report the separation of the enantiomers of rac‐fenoterol and that R‐F is the active component of rac‐fenoterol. Further evaluation of R‐F will determine if it has enhanced selectivity and specificity for β2‐AR/Gs activation and if it can be used in the treatment of congestive heart failure. Chirality, 2006. Published 2006 Wiley‐Liss, Inc.


  • Mapping the Dose–Effect Relationship of Orbofiban from Sparse Data with an Artificial Neural Network

    by Donald E. Mager, Jason D. Shirey, Dermot Cox, Desmond J. Fitzgerald, Darrell R. Abernethy


  • Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability

    by Mirna Urquidi‐Macdonald, Donald E. Mager, Mary A. Mascelli, Bart Frederick, Jane Freedman, Desmond J. Fitzgerald, Neal S. Kleiman, Darrell R. Abernethy

    Objective Our objective was to develop a computational model for predicting abciximab‐induced inhibition of ex vivo platelet aggregation from the administered dose and readily available patient clinical characteristics by use of a neural network approach. Methods A back‐propagation neural network was designed to establish the relationship between abciximab dosing, patient clinical history, and effect (inhibition of 20 μmol/L adenosine diphosphate–induced ex vivo platelet aggregation). The neural network was trained by use of data from 8 (out of 47) patients undergoing coronary angioplasty and 30 healthy individuals. Final neuron connection weights were used to evaluate significant patient covariates. The final neural network was validated via (1) predicting the effects of the validation database (remaining 39 patients) and (2) predicting the individual patient doses to achieve 20% of baseline platelet aggregation. Results The trained neural network successfully captured the complex pharmacodynamic profiles of abciximab without specifying a structural model and identified several patient covariates that significantly contribute to establishing the abciximab dose‐effect relationship, including stable angina with nitrate treatment, previous myocardial infarction, and smoking. A wide distribution of individual bolus doses of abciximab was predicted, suggesting the potential for dosing individualization while improving the risk of adverse drug events. The mean predicted dose (16.9 mg) was in agreement with the results from a previously published concentration‐effect relationship for abciximab (18.9 ± 2.0 mg). Conclusions These findings suggest the usefulness of neural network methods to individualize dosing for drugs with a narrow therapeutic index when real‐time measures of drug concentration and effect are unavailable, but future clinical studies are required for prospective validation. Clinical Pharmacology & Therapeutics (2004) 75, 60–69; doi: 10.1016/j.clpt.2003.09.008


  • Open Access

    International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

    by W. A. Catterall, K. G. Chandy, D. E. Clapham, G. A. Gutman, F. Hofmann, A. J. Harmar, D. R. Abernethy, M. Spedding


  • Pharmacodynamics of abciximab during angioplasty: Comparison to healthy subjects

    by Darrell R. Abernethy, John Pezzullo, Mary A. Mascelli, Bart Frederick, Neal S. Kleiman, Jane Freedman

    Objectives: Our objectives were to compare and contrast abciximab concentration‐effect relationships in healthy volunteer participants with those in patients with coronary atherosclerosis undergoing elective coronary angioplasty. We also aimed to establish abciximab plasma concentrations associated with 80% inhibition of platelet aggregation.Methods: Abciximab clearance and concentration‐effect relationships were determined from two separate clinical studies, one in 30 healthy subjects aged 21 to 66 years and the other in 32 patients aged 44 to 74 years before they underwent elective coronary angioplasty. After abciximab administration, abciximab plasma concentrations, platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor occupancy, and degree of inhibition of platelet aggregation in the presence of 5‐μmol/L and 20‐μmol/L adenosine diphosphate was determined. With an Emax (receptor occupancy) or inhibitory Emax (inhibition of platelet aggregation) model, abciximab concentrations required for 80% receptor occupancy and 80% inhibition of platelet aggregation were determined.Results: Abciximab steady‐state clearance in healthy participants was 183 ± 72 ml/min (mean ± SD), and single‐dose clearance in patients undergoing angioplasty was 405 ± 240 ml/min (mean ± SD). Abciximab concentration required for 80% GP IIb/IIIa receptor occupancy was 35.2 ± 2.4 versus 72.8 ± 6.4 ng/ml in healthy participants versus patients (P < .01). Concentrations required for 80% inhibition of platelet aggregation stimulated by 5‐μmol/L adenosine diphosphate were 25.6 ± 1.6 versus 68.9 ± 9.2 ng/ml (P < .01). Similarly, the concentrations required for 80% inhibition of platelet aggregation stimulated by 20‐μmol/L adenosine diphosphate were 56.0 ± 3.2 versus 141 ± 16.8 ng/ml (P < .01).Conclusion: Approximately 2‐fold greater abciximab exposure is required to achieve the same degree of GP IIb/IIIa occupancy and inhibition of platelet aggregation in patients undergoing angioplasty as compared with healthy participants. The difference between groups may be related either to different states of basal platelet activation or to the effect of heparin that patients received as part of the angioplasty procedure. A therapeutic concentration range for patients is 100 to 175 ng/ml, because this is the concentration consistent with >80% inhibition of platelet aggregation when 20‐μmol/L adenosine diphosphate is used as the aggregating stimulus.Clinical Pharmacology & Therapeutics (2002) 71, 186–195; doi: 10.1067/mcp.2002.121775


  • Stereoselective halofantrine disposition and effect:concentration-related QTc prolongation

    by Darrell R. Abernethy, David L. Wesche, Jean T. Barbey, Colin Ohrt, Sarina Mohanty, John C. Pezzullo, Brian G. Schuster


  • Molecular Basis of Cardiovascular Drug Metabolism

    by Darrell R. Abernethy, David A. Flockhart